Mesenchymal stem cell‑neural progenitors (MSC‑NPs) are a population derived from bone marrow mesenchymal stem cells with reported trophic and immunomodulatory properties. These biological characteristics have motivated investigation of MSC‑NPs as a therapeutic approach in multiple sclerosis (MS), particularly in progressive forms of the disease where effective reparative and immunomodulatory strategies are needed. Early phase clinical trials have evaluated intrathecal administration of autologous MSC‑NPs to better target the central nervous system compartment.
Cerebrospinal fluid (CSF) biomarker analyses were performed on participants drawn from two separate cohorts of clinical trial subjects with progressive MS. One cohort came from a phase 2 trial (n = 50) and the other from an expanded access trial (n = 43). Subjects in both cohorts had either secondary progressive or primary progressive MS and received repeated administrations of autologous MSC‑NPs delivered intrathecally. The abstract reports the biomarker evaluation across these two independently treated cohorts.
Candidate biomarkers were first identified via proteomic screening of CSF. Those candidates were then validated in both the phase 2 and expanded access cohorts. The multi‑step approach—screening followed by cross‑cohort validation—was used to identify biomarkers that consistently respond to MSC‑NP treatment in the CSF compartment.
Validation across the two cohorts revealed a panel of four CSF biomarkers that were significantly changed following MSC‑NP injections. The four biomarkers identified are:
The abstract emphasizes that these changes were observed in CSF after treatment, indicating compartmentalized biological responses to intrathecal MSC‑NP administration.
The biomarker changes noted above were specific to CSF and were not mirrored in serum. This distinction underscores a localized CNS effect following intrathecal MSC‑NP injections and supports the use of CSF sampling to detect pharmacodynamic responses for therapies administered directly to the central nervous system.
Two commonly measured MS biomarkers—neurofilament light (NfL) and glial fibrillary acidic protein (GFAP)—were evaluated in the same dataset. The abstract reports that neither NfL nor GFAP changed following MSC‑NP treatment. However, these biomarkers demonstrated clinically relevant correlations: NfL correlated with age, while GFAP correlated with both age and Expanded Disability Status Scale (EDSS). These associations indicate that NfL and GFAP reflect background variables and disease severity rather than acute pharmacodynamic effects of MSC‑NP injections in this analysis.
The observation that a defined panel of four CSF biomarkers changed after intrathecal MSC‑NP administration suggests that MSC‑NP injections elicit discrete biological effects within the central nervous system that are detectable in CSF. Because the changes were not observed in serum, the results highlight a central, compartmentalized pharmacodynamic signature of treatment rather than a systemic signal.
These specific biomarker shifts provide a molecular readout that helps define the biological response to MSC‑NP therapy. By identifying markers that respond consistently across two cohorts, the work offers candidate measures that can be used to monitor engagement of biological pathways targeted by MSC‑NPs in future studies.
The panel of CSF biomarkers (CCL2, MMP9, SCF, CHIT1) reported to change after MSC‑NP injections can inform the design of subsequent clinical investigations in progressive MS. These biomarkers may serve as pharmacodynamic endpoints to detect and quantify CNS responses to intrathecally administered cell therapies. The lack of change in serum values emphasizes the importance of CSF sampling when evaluating centrally delivered interventions.
The abstract notes that NfL and GFAP did not change with treatment but were correlated with age and disability (EDSS), which supports continued use of these biomarkers for capturing outcomes related to neurodegeneration and disease burden rather than acute treatment response.
The abstract summarizes proteomic screening, cross‑cohort validation, identification of a four‑marker CSF panel altered after MSC‑NP treatment, and correlations of NfL and GFAP with age and EDSS. Specific numerical values, effect sizes, statistical metrics, safety data, timing of sample collection relative to injections, and longer‑term clinical efficacy outcomes are not reported in the abstract. Those details would need to be obtained from the full published manuscript for comprehensive assessment.
In people with progressive MS treated with repeated intrathecal autologous MSC‑NP administrations across two cohorts (phase 2 and expanded access), a reproducible CSF biomarker signature comprising CCL2, MMP9, SCF, and CHIT1 was identified. These changes were confined to CSF and not present in serum, suggesting localized CNS biological effects and providing candidate pharmacodynamic markers to guide future clinical study design.